We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of Biomarkers in Susac Syndrome

This study is currently recruiting participants.
Verified April 2017 by Jan-Markus Dörr, Charite University, Berlin, Germany
Sponsor:
ClinicalTrials.gov Identifier:
NCT01273792
First Posted: January 11, 2011
Last Update Posted: April 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Jan-Markus Dörr, Charite University, Berlin, Germany
January 6, 2011
January 11, 2011
April 14, 2017
May 2010
December 2017   (Final data collection date for primary outcome measure)
  • disease specific patterns of pathology on cranial MRI
    one-time cranial MRI
  • disease specific patterns of pathology in optical coherence tomography
    one time optical coherence tomography
  • serological biomarkers [ Time Frame: not defined, cross-sectional analysis ]
Same as current
Complete list of historical versions of study NCT01273792 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Investigation of Biomarkers in Susac Syndrome
Investigation of Relevant Biomarkers in Patients With Susac Syndrome
Susac Syndrome is a rare disease and the establishment of the diagnosis is often difficult. The aim of this investigation is to identify relevant biomarkers and to elucidate the pathogenesis of Susac syndrome

Susac Syndrome is a rare disease characterized by encephalopathy, branch retinal artery occlusion and sensorineural deafness. The pathogenesis is not yet clear, an autoimmune endotheliopathy is discussed. Because of the variable and often incomplete clinical presentation, the establishment of the diagnosis is often delayed or even completely missed.

The aim of this study is to identify biomarkers that facilitate the reliable and prompt establishment of the diagnosis. Patients with a definite diagnosis of Susac syndrome and healthy subjects as controls are investigated.

Furthermore, the correlation of serological markers with structural retinal and cerebral changes will contribute to clarification of the pathogenesis of Susac syndrome.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Blood samples (serum, Blood cells)
Probability Sample
patients with Susac syndrome (male/female; healthy control subjects
Susac Syndrome
Not Provided
  • Patients with Susac syndrome
  • Matched healthy controls
Dörr J, Radbruch H, Bock M, Wuerfel J, Brüggemann A, Wandinger KP, Zeise D, Pfueller CF, Zipp F, Paul F. Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome. Nat Rev Neurol. 2009 Dec;5(12):683-8. doi: 10.1038/nrneurol.2009.176.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
December 2017
December 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • adult male and female patients with definite Susac syndrome or matching healthy control subjects
  • ability to provide informed consent

Exclusion Criteria:

  • pregnancy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact: Jan M Dörr, MD +49 30 450 ext 660162 jan-markus.doerr@charite.de
Germany
 
 
NCT01273792
Biomarkers Susac Syndrome
No
Not Provided
Not Provided
Jan-Markus Dörr, Charite University, Berlin, Germany
Charite University, Berlin, Germany
Not Provided
Principal Investigator: Jan M Dörr, MD NeuroCure Clinical Research Center, Charité Universitaetsmedizin Berlin
Charite University, Berlin, Germany
April 2017